Human VEGF-A ELISA

Sample

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cell culture supernatant

Species Reactivity

Human

Detection Method

sELISA

Intended Use

The Human VEGF-A ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of Human VEGF-A. The Human VEGF-A ELISA is for in vitro diagnostic use. Not for use in therapeutic procedures.

Contents of Kit

1 vial (120 μl) Biotin-Conjugate anti-Human VEGF-A polyclonal antibody
1 vial (150 μl) Streptavidin-HRP
2 vials Human VEGF-A Standard lyophilized, 2 ng/ml upon reconstitution
1 vial (12 ml) Sample Diluent
1 vial (5 ml) Assay Buffer Concentrate 20× (PBS with 1% Tween 20 and 10% BSA)
1 bottle (50 ml) Wash Buffer Concentrate 20× (PBS with 1% Tween 20)
1 vial (15 ml) Substrate Solution (tetramethyl-benzidine)
1 vial (15 ml) Stop Solution (1M Phosphoric acid)

Storage

Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Detection Range

15.6-1000 pg/ml

Detection Limit

7.9 pg/ml

Sensitivity

The limit of detection of Human VEGF-A defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 7.9 pg/ml (mean of 6 independent assays).

General Description

Normal tissue function depends on a regular supply of oxygen through the blood vessels. Understanding the formation of blood vessels has become the focus of a major research effort throughout the last decade. Vasculogenesis in the embryo is the process by which new blood vessels are generated de novo from primitive precursor cells. Angiogenesis is the process of new blood vessel formation from pre-existing vasculatures. It plays an essential role in development, normal tissue growth, wound healing, the female reproductive cycle (placental development, ovulation, corpus luteum) and also plays a major role in various diseases. Special interest is focused on tumor growth, since tumors cannot grow more than a few millimeters in size without developing a new blood supply. This process is described as tumor angiogenesis which is also essential for the spread and growth of tumor cell metastasis. One of the key molecules for angiogenesis and for the survival of the endothelium is vascular endothelial growth factor (VEGF-A). It is a specific endothelial cell mitogen and a strong vascular permeability factor (VPF). VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell types. VEGF-A also causes vasodilation through the nitiric oxide synthase pathway in endothelial cells and can activate migration in monocytes. Many different splice variants of VEGF-A have been described, but VEGF165 is the most predominant protein and anchors with its heparin binding domain to extracellular matrix and to heparin sulfate. During the past few years, several other members of the VEGF family have been cloned, including VEGF-B, -C and -D. In terms of vascular angiogenesis, which mainly is regulated by VEGF-A, lymphangiogenesis is mainly regulated by VEGF-C and -D.

Standard Curve